Vancouver-based Algernon Health (CSE:AGN, OTCQB:AGNPF) is charting a new course in healthcare, setting its sights on one of the fastest-growing frontiers: neuroimaging for Alzheimer’s disease. Once a drug-repurposing company known as Algernon Pharmaceuticals, the firm has pivoted into medtech, unveiling a brain-focused PET scanner and laying the groundwork for a network of dedicated imaging centers across North America.
This week, the company announced a strategic partnership with American Molecular Imaging, a US-based radiology group of roughly 80 specialists. Not only will the group serve as the exclusive reader of Algernon’s PET scans, but it is also putting its money where its expertise is, making a financial investment in the company. CEO Christopher Moreau framed the move as both a strategic and financial endorsement. “We’ve retained them to read our patient’s PET scans for us, and now they’ve written us a check. So what does that say about our new PET technology?”
Recently, Algernon finalized an equipment order with Catalyst MedTech, which holds exclusive US rights to the brain-specific PET scanner in North America. Catalyst is providing $4 million in non-dilutive financing to support the deployment of the first four scanners, helping to reduce capital risk as Algernon prepares to launch its first clinics.
A scanner built for the brain
Algernon’s PET technology differs from traditional PET/CT systems by focusing exclusively on the brain. By eliminating the CT component, the scanner reduces radiation exposure by roughly 25%, a meaningful benefit for patients who may require multiple scans over time. PET scanners are specifically and uniquely designed to detect amyloid plaques, which is the hallmark of Alzheimer’s disease, and offers a non-invasive alternative to spinal taps.
The timing could not be better. FDA-approved antibody therapies from Eli Lilly and Biogen now require confirmatory testing to identify eligible patients. “If someone presents to a physician with memory loss or cognitive dysfunction… patients need a confirmatory test to show plaque in the brain in order to be eligible for the new Alzheimer’s treatments. You can do that with a spinal tap—ouch—or a PET scan. That’s where we come in,” Moreau explained.
A market ripe for innovation
Alzheimer’s currently affects roughly seven million Americans, with another seven million expected within the next five to seven years. Yet only about 10% of US PET /CT scan capacity is focused on the brain, leading to bottlenecks and long waits at hospital imaging departments.
Algernon plans to address this gap with small, turnkey neuroimaging centers, each roughly 1,500 to 1,700 square feet, staffed by a team of two staff, and equipped with a single scanner. These clinics will target neurologists, geriatricians, and primary care physicians, while also catering to adults in their 50s and 60s seeking practical, out-of-pocket early detection. Clinical trials offer another potential revenue stream. “One center is not going to change the needle. But as we open up five, 10, 20 centers, we have a network that can start partnering with larger contract research organizations,” Moreau said.
Scaling the vision
The company aims to open its first US brain imaging center by spring and ultimately build a network across North America. The compact, replicable design, combined with strategic partners like Catalyst MedTech and American Molecular Imaging, positions Algernon to scale efficiently while managing operational complexity.
Of course, challenges remain. Nuclear imaging facilities must navigate strict regulatory requirements and be located near cyclotrons that produce short-lived PET tracers. Any regulatory delays or logistical hurdles could slow expansion. Scaling from a few pilot centers to a national presence will also require careful execution.
Yet Algernon Health’s pivot into Alzheimer’s diagnostics comes at an inflection point in healthcare. Proprietary, brain-optimized PET technology, backing from a strategic investor-partner, and non-dilutive financing all give the company a foundation to tackle a massive, under-served market.